PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1190545
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1190545
The dental biomaterials market was valued at about USD 6,464.75 million in 2021, and it is expected to reach USD 9,487.13 million by 2027, recording a CAGR of 6.77% over the forecast period 2022-2027.
The impact of the COVID-19 pandemic on the market was significant as several elective procedures, including dental treatments, were halted or postponed during the pandemic. In March 2020, the American Dental Association (ADA) recommended postponing all elective dental procedures until April 6, 2020, and providing emergency-only dental services to keep patients from burdening hospital emergency departments. This recommendation was updated on April 1, 2020, when the ADA advised offices to remain closed except for urgent and emergency procedures until April 30, owing to the rise of COVID-19 cases. As a result, access to dental care substantially decreased. Also, as per data published by the British Dental Association, in July 2020, out of 2,053 dentists, only 36% were ready to resume dental practices in United Kingdom. During the initial phase of the pandemic, dental services and treatments were delayed, which resulted in decreased demand for dental biomaterials and affected market growth adversely. However, the market is gaining traction as elective dental procedures have resumed worldwide owing to the declining severity and infections of COVID-19.
Further, the major factors fueling the market growth include the rising burden of dental disorders, growing dental tourism, growing penetration of dental implants, and increasing disposable income across developing countries.
The rising burden of dental disorders and growing dental tourism are major factors driving the market growth. The growing burden of dental diseases such as periodontal disease, tooth decay, oral cancer, halitosis, and dental caries, among other diseases, is driving the market growth. For instance, as per a March 2020 update by the World Health Organization (WHO), it is estimated that oral diseases affect nearly 3.5 billion people globally, especially severe periodontal (gum) disease. Also, an article titled "Dental Tourism 2021: Get Cheaper Dental Implants and Veneers Abroad," published in Dentaly.org in December 2021, stated that dental implant tourism is a growing business attributed to cost savings. Such factors are thereby increasing the adoption of dental procedures among patients and are expected to drive the demand for dental biomaterials over the coming years.
Nevertheless, regulatory issues and the cost of procedures are some of the factors restraining the market growth.
By type, metallic biomaterials are expected to witness significant growth. Metallic biomaterials are a central class of materials for use in dental treatments. This can be attributed to the high strength and other mechanical properties associated with these materials. These biomaterials are extensively used to fabricate surgical implants owing to load-bearing characteristics and fatigue properties, such as titanium, gallium, and silicon.
As per an article published in November 2021, titled "Editorial: Metallic Biomaterials for Medical Applications," titanium alloys are widely used for dental and implant materials due to their superior biocompatibility, corrosion resistance, and specific strength compared with other metallic implant materials. In addition, as per an article titled, "Review of Metallic Biomaterials in Dental Applications," published in August 2020, Ti-Ga-Si is considered to combine the advantages of the Ti-Ga alloy along with Si, which enhances the osseointegration with aesthetically pleasing outcomes for patients and minimal likelihood of medical complications.
Such studies indicate the efficacy of metallic biomaterials and are expected to generate significant demand for metallic implants, thus positively impacting the segment's growth.
Within North America, United States is expected to observe significant growth. With the increase in product launches supported by government authorities, the rising burden of dental diseases and the increasing geriatric population are bolstering the demand for dental biomaterials in United States.
For instance, as per the American Dental Association, in 2020, more than 5 million US seniors aged 65 to 74 had complete tooth loss, with nearly 3 million suffering from edentulous. Tooth loss, on the other hand, is primarily a problem for the elderly. This is because 91% of adults aged 20 to 64 have dental caries, with a staggering 27% going untreated. Furthermore, tooth decay is a common cause of tooth loss in many cases. Thus, such factors are anticipated to boost the total dental procedures performed across United States, thereby boosting the demand for dental biomaterials within the country.
Furthermore, several market players are also engaged in implementing strategic initiatives, thereby propelling market growth. For instance, in January 2020, Pulpdent Corporation, a dental research and manufacturing company based in the Greater Boston area, launched its ACTIVA Presto dental material. The new white dental filling material mimics the properties of natural teeth. Moreover, in April 2021, Ultradent Products Inc., a developer and manufacturer of high-tech dental materials and equipment, purchased majority ownership in Vamasa SA de CV, a premier distributor of dental products in Mexico.
Thus, in view of the abovementioned factors, the market is expected to witness significant growth in the region over the forecast period.
The dental biomaterials market is moderately competitive, with the presence of local and international players in the market. The major share of the market has been grabbed by global players, whereas small to mid-sized companies are posing intense competition with the help of novel technologies. In the future, it is expected that the market share will be distributed among international players and small players as well due to the focus of new entrants to come up with innovative products. Some of the major players in the market are Straumann Holding AG, Dentsply Sirona Inc., 3M Company, ZimVie Inc., and Botiss Biomaterials GmbH.